NASDAQ:CDXCChromadex Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Chromadex Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.82 -0.03 (-0.62 %) (As of 08/14/2020 12:43 PM ET) Add Compare Share Today's Range$4.80Now: $4.82▼$4.8350-Day Range$4.35MA: $4.89▼$5.2652-Week Range$2.50Now: $4.82▼$5.80Volume453 shsAverage Volume395,714 shsMarket Capitalization$297.03 millionP/E RatioN/ADividend YieldN/ABeta1.63 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingChromadex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.33, Chromadex has a potential upside of 29.8% from its current price of $4.88.Amount of Analyst CoverageChromadex has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesChromadex has received 489 “outperform” votes. (Add your “outperform” vote.)Underperform VotesChromadex has received 536 “underperform” votes. (Add your “underperform” vote.)Community SentimentChromadex has received 52.29% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote “Outperform” if you believe CDXC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldChromadex does not currently pay a dividend.Dividend GrowthChromadex does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chromadex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,550.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 12.92% of the stock of Chromadex is held by insiders.Percentage Held by InstitutionsOnly 20.75% of the stock of Chromadex is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chromadex are expected to grow in the coming year, from ($0.41) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chromadex is -11.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chromadex is -11.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChromadex has a P/B Ratio of 13.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.91 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDXC Previous Symbol CUSIPN/A CIK1386570 Webwww.chromadex.com Phone310-388-6706Debt Debt-to-Equity Ratio0.03 Current Ratio2.23 Quick Ratio1.46Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$46.29 million Price / Sales6.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book13.77Profitability EPS (Most Recent Fiscal Year)($0.52) Net Income$-32,150,000.00 Net Margins-46.86% Return on Equity-103.66% Return on Assets-55.19%Miscellaneous Employees100 Outstanding Shares61,624,000Market Cap$297.03 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $4.82 -0.03 (-0.62 %) (As of 08/14/2020 12:43 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CDXC News and Ratings via Email Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter. Chromadex (NASDAQ:CDXC) Frequently Asked Questions How has Chromadex's stock price been impacted by Coronavirus? Chromadex's stock was trading at $3.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CDXC shares have increased by 31.0% and is now trading at $4.82. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Chromadex? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chromadex. When is Chromadex's next earnings date? Chromadex is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Chromadex. How were Chromadex's earnings last quarter? Chromadex Corp (NASDAQ:CDXC) announced its earnings results on Thursday, August, 6th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.05. Chromadex had a negative return on equity of 103.66% and a negative net margin of 46.86%. View Chromadex's earnings history. What price target have analysts set for CDXC? 3 brokerages have issued twelve-month price targets for Chromadex's shares. Their forecasts range from $6.00 to $7.00. On average, they expect Chromadex's stock price to reach $6.33 in the next year. This suggests a possible upside of 31.4% from the stock's current price. View analysts' price targets for Chromadex. Has Chromadex been receiving favorable news coverage? News articles about CDXC stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Chromadex earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news about Chromadex. Are investors shorting Chromadex? Chromadex saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 2,850,000 shares, a decrease of 17.9% from the April 15th total of 3,470,000 shares. Based on an average daily volume of 526,800 shares, the short-interest ratio is currently 5.4 days. Currently, 7.5% of the company's shares are sold short. View Chromadex's Short Interest. Who are some of Chromadex's key competitors? Some companies that are related to Chromadex include Aurora Cannabis (ACB), Tilray (TLRY), Canopy Rivers (RIV), Mediwound (MDWD), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), True Drinks (TRUU), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC) and Beleave (BE). View all competitors. What other stocks do shareholders of Chromadex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chromadex investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), Tilray (TLRY), Athersys (ATHX), Glu Mobile (GLUU), TransEnterix (TRXC), BioNano Genomics (BNGO) and DHT (DHT). Who are Chromadex's key executives? Chromadex's management team includes the following people: Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 51)Mr. Robert N. Fried, CEO & Director (Age 59)Mr. Kevin M. Farr, Chief Financial Officer (Age 61)Mr. Ben Shichman, Chief Technology OfficerDr. Matthew Roberts, Chief Scientific Officer & Sr. VP of Innovation What is Chromadex's stock symbol? Chromadex trades on the NASDAQ under the ticker symbol "CDXC." Who are Chromadex's major shareholders? Chromadex's stock is owned by many different institutional and retail investors. Top institutional investors include Sycale Advisors NY LLC (0.59%), UBS Group AG (0.33%), Bank of New York Mellon Corp (0.21%), Bessemer Group Inc. (0.19%), Raymond James Financial Services Advisors Inc. (0.14%) and California Public Employees Retirement System (0.13%). Company insiders that own Chromadex stock include Kevin M Farr, Robert N Fried and Stephen A Block. View institutional ownership trends for Chromadex. Which institutional investors are selling Chromadex stock? CDXC stock was sold by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC, Miracle Mile Advisors LLC, UBS Group AG, Bank of New York Mellon Corp, and Raymond James Financial Services Advisors Inc.. View insider buying and selling activity for Chromadex. Which institutional investors are buying Chromadex stock? CDXC stock was acquired by a variety of institutional investors in the last quarter, including Bessemer Group Inc., California Public Employees Retirement System, Sycale Advisors NY LLC, SG Americas Securities LLC, Insight 2811 Inc., and Goldman Sachs Group Inc.. Company insiders that have bought Chromadex stock in the last two years include Kevin M Farr, and Robert N Fried. View insider buying and selling activity for Chromadex. How do I buy shares of Chromadex? Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Chromadex's stock price today? One share of CDXC stock can currently be purchased for approximately $4.82. How big of a company is Chromadex? Chromadex has a market capitalization of $297.03 million and generates $46.29 million in revenue each year. The company earns $-32,150,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chromadex employs 100 workers across the globe. What is Chromadex's official website? The official website for Chromadex is www.chromadex.com. How can I contact Chromadex? Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
